News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum

Posted on

TFS Corporation Limited announced that its pharmaceutical partner ViroXis has received Institutional Review Board approval to initiate Federal Drug Administration phase 2 study for the treatment of molluscum contagiosum using TFS’s East Indian sandalwood oil. IRB approval is a prerequisite to initiate clinical studies in the United States for prescription drugs. Frank Wilson, CEO of TFS, said. “This is another […]Read More ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum

San Antonio Biotech Firm Readies Skin Treatment for Distribution

Posted on

ViroXis Corp. has signed a licensing agreement with a global pharmaceutical company to market over-the-counter products containing sandalwood oil. The San Antonio-based biotech company has been working to develop a treatment for skin warts using byproducts of the East Indian Sandalwood tree. The company recently wrapped up a Phase 2 clinical study of its treatment for the Human Papilloma Virus […]Read More San Antonio Biotech Firm Readies Skin Treatment for Distribution